Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 91

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 91
---
 payable by us, and assuming exercise in full of any pre-funded warrants offered in this offering, no exercise of the Warrants being offered in this offering, that no value is attributed to such Warrants and that such Warrants are classified as and accounted for as equity. |

You should read this table together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as our financial statements and related notes and the other financial information appearing elsewhere in this prospectus. The information presented in the capitalization table has been adjusted to reflect the effect of this current offering.

| ​                                                                                                                                                                                            | ​ | ​ 
 ​ | As of September 30, 2024 |   | ​ |             |
|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|-------------------------:|:--|:--|:------------|
| (in thousands, except share and per share amounts)                                                                                                                                           | ​ | ​ |                   Actual |   | ​ | As adjusted |
| Cash and cash equivalents                                                                                                                                                                    | ​ | $ |                    3,525 | ​ | $ | ​           |
| Stockholders’ equity                                                                                                                                                                         | ​ | ​ |                        ​ | ​ | ​ | ​           |
| Common stock, par value $0.0001 per share; 200,000,000 shares authorized at September 30, 2024; 36,827,671 shares issued and outstanding, actual; shares issued and outstanding, as adjusted | ​ | ​ |                        3 | ​ | ​ | ​           |
| Additional paid-in capital                                                                                                                                                                   | ​ | ​ |                  387,112 | ​ | ​ | ​           |
| Accumulated deficit                                                                                                                                                                          | ​ | ​ |                 -395,771 | ​ | ​ | ​           |
| Total stockholders’ equity/(deficit)                                                                                                                                                         | ​ | $ |                   -8,656 | ​ | $ | ​           |
| Total capitalization                                                                                                                                                                         | ​ | $ |                   -8,656 | ​ | $ | ​           |

The foregoing discussion and tables above are based on 36,827,671 shares of common stock outstanding as of September 30, 2024, and excludes:

| ● | 76,112 shares of our common stock issuable upon the exercise of outstanding stock options as of September 30, 2024, with a weighted-average exercise price of $85.95 per share; |

| ● | 11,379 shares of common stock issuable upon the vesting